<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086033</url>
  </required_header>
  <id_info>
    <org_study_id>PMOS GREC 2004 06</org_study_id>
    <nct_id>NCT01086033</nct_id>
  </id_info>
  <brief_title>A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece</brief_title>
  <official_title>A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe RA Treated With Humira in Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to observe and assess the long-term use, safety and efficacy
      of Humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and
      in accordance with the terms of the European marketing authorization and to observe
      compliance of patients with the prescribed treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, uncontrolled observational study of patients who at the time of entry
      had moderate to severe rheumatoid arthritis (RΑ) and who were subsequently prescribed Humira
      (adalimumab) following normal clinical practice, with or without other anti-rheumatic
      treatments, prior to enrollment in this study.

      Once the physician has determined that the patient meets the inclusion criteria, and the
      patient has agreed to be included in the observational study by signing the informed consent,
      the patient's Day 1 demographic data, and disease status will be reported in the Day 1 Data
      Report Forms. The physician will then follow-up with the patient via regular office visits at
      intervals as determined by routine clinical practice. Patient's safety and efficacy data, if
      they are part of clinical routine, will be recorded in the Data Report Forms at Day 1, and
      regular visits which are closest to Month 3, Month 6, Month 9, Month 12, Month 18, Month 24,
      Month 30, and Month 36.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, is an event that results in a condition that substantially interferes with the activities of daily living of the participant, is an important medical event requiring medical or surgical intervention to prevent a serious outcome, spontaneous abortion or miscarriage experienced by the participant, or an elective abortion performed on the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score (DAS) 28 Over Time</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity.
A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of &gt; 1.2 compared with Baseline and attainment of a DAS28 score of ≤ 3.2.
A Moderate EULAR Response is defined as either:
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 from Baseline and attainment of a DAS28 score of ≤ 5.1, or
an improvement (decrease) in the DAS28 of &gt; 1.2 from Baseline and attainment of a DAS28 score of &gt; 3.2.
No Response is defined as either:
an improvement (decrease) in the DAS28 of ≤ to 0.6, or
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 and attainment of a DAS28 of &gt; 5.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an American College of Rheumatology (ACR) 20 Response</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an American College of Rheumatology (ACR) 50 Response</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an American College of Rheumatology (ACR) 70 Response</measure>
    <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Missed at Least One Dose of Humira</measure>
    <time_frame>Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>Compliance to study treatment was measured by the percentage of participants who missed at least one dose of Humira during each time interval between study visits.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">566</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Humira</arm_group_label>
    <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Rheumatoid Arthritis on Humira (adalimimab) treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate or severe active rheumatoid arthritis, who have been prescribed
             and are receiving Humira (adalimumab) under normal clinical practice for at least one
             month prior to inclusion and according to the approved Summary of Product
             Characteristics (SPC) in the European Union.

          -  Patients must be willing to consent to data being collected and provided to Abbott
             Laboratories.

        Exclusion Criteria:

          -  Contraindications according to the SPC.

          -  Patients should not participate in another observational Abbott study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanasis Floros, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie Pharmaceuticals S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30116</name>
      <address>
        <city>A. Glyfada</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47544</name>
      <address>
        <city>Ag. Dimitrios, Athens</city>
        <zip>17121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47542</name>
      <address>
        <city>Ag. Paraskevi, Athens</city>
        <zip>15343</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29992</name>
      <address>
        <city>Agioi Anargyroi</city>
        <zip>13122</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29954</name>
      <address>
        <city>Agioi Anargyroi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29915</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30118</name>
      <address>
        <city>Arta</city>
        <zip>47100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29989</name>
      <address>
        <city>Athens</city>
        <zip>10444</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29914</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29950</name>
      <address>
        <city>Athens</city>
        <zip>115 25</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5284</name>
      <address>
        <city>Athens</city>
        <zip>115 25</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29944</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30474</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29953</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30085</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30472</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30479</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30480</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29899</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30178</name>
      <address>
        <city>Athens</city>
        <zip>11635</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30785</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30788</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30198</name>
      <address>
        <city>Chalkida</city>
        <zip>34100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30008</name>
      <address>
        <city>Crete</city>
        <zip>71201</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30210</name>
      <address>
        <city>Crete</city>
        <zip>74100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29828</name>
      <address>
        <city>Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30105</name>
      <address>
        <city>Drama</city>
        <zip>66100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29820</name>
      <address>
        <city>Elefsina</city>
        <zip>19200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30146</name>
      <address>
        <city>Ermoupolis Syros</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30767</name>
      <address>
        <city>Heraklion Crete</city>
        <zip>70013</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30789</name>
      <address>
        <city>Holargos</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30482</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47322</name>
      <address>
        <city>Karditsa</city>
        <zip>43100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29850</name>
      <address>
        <city>Katerini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30189</name>
      <address>
        <city>Kavala</city>
        <zip>65302</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30476</name>
      <address>
        <city>Kifisia</city>
        <zip>14500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30004</name>
      <address>
        <city>Kozani</city>
        <zip>50100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29993</name>
      <address>
        <city>Lamia</city>
        <zip>35100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29988</name>
      <address>
        <city>Larisa</city>
        <zip>41223</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30770</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29922</name>
      <address>
        <city>Nikea</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29972</name>
      <address>
        <city>Patras</city>
        <zip>26221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29916</name>
      <address>
        <city>Patras</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29827</name>
      <address>
        <city>Peristeri</city>
        <zip>12134</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29936</name>
      <address>
        <city>Pyrgos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30200</name>
      <address>
        <city>Rion, Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29900</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54622</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30192</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54622</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30165</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54623</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30765</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29845</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30791</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30792</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47543</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29924</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55134</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30477</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29947</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30115</name>
      <address>
        <city>Trikala</city>
        <zip>42100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30084</name>
      <address>
        <city>Veria</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29968</name>
      <address>
        <city>Xanthi</city>
        <zip>67100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <results_first_submitted>July 17, 2013</results_first_submitted>
  <results_first_submitted_qc>September 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2013</results_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evaluation of safety and efficacy</keyword>
  <keyword>Adalimumab treatment</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Humira</title>
          <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="566"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of efficacy/Exacerbation of RA</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE and Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent and Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent and Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE and Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE and Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE and Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, Withdrew Consent &amp; Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Humira</title>
          <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, is an event that results in a condition that substantially interferes with the activities of daily living of the participant, is an important medical event requiring medical or surgical intervention to prevent a serious outcome, spontaneous abortion or miscarriage experienced by the participant, or an elective abortion performed on the participant.</description>
        <time_frame>3 years</time_frame>
        <population>The safety population, including all patients that received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, is an event that results in a condition that substantially interferes with the activities of daily living of the participant, is an important medical event requiring medical or surgical intervention to prevent a serious outcome, spontaneous abortion or miscarriage experienced by the participant, or an elective abortion performed on the participant.</description>
          <population>The safety population, including all patients that received at least one dose of the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Activity Score (DAS) 28 Over Time</title>
        <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population; &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS) 28 Over Time</title>
          <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Safety population; &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=555)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=449)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=401)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=379)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>European League Against Rheumatism (EULAR) Response</title>
        <description>A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity.
A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of &gt; 1.2 compared with Baseline and attainment of a DAS28 score of ≤ 3.2.
A Moderate EULAR Response is defined as either:
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 from Baseline and attainment of a DAS28 score of ≤ 5.1, or
an improvement (decrease) in the DAS28 of &gt; 1.2 from Baseline and attainment of a DAS28 score of &gt; 3.2.
No Response is defined as either:
an improvement (decrease) in the DAS28 of ≤ to 0.6, or
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 and attainment of a DAS28 of &gt; 5.1.</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population;</population>
        <group_list>
          <group group_id="O1">
            <title>Good Response</title>
            <description>Rheumatoid Arthritis patients treated with Humira (adalimumab) with a Good Response per EULAR criteria.</description>
          </group>
          <group group_id="O2">
            <title>Moderate Response</title>
            <description>Rheumatoid Arthritis patients treated with Humira (adalimumab) with a Moderate Response per EULAR criteria.</description>
          </group>
          <group group_id="O3">
            <title>No Response</title>
            <description>Rheumatoid Arthritis patients treated with Humira (adalimumab) with No Response according to EULAR criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>European League Against Rheumatism (EULAR) Response</title>
          <description>A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity.
A Good EULAR Response is defined as an improvement (decrease) in the DAS28 of &gt; 1.2 compared with Baseline and attainment of a DAS28 score of ≤ 3.2.
A Moderate EULAR Response is defined as either:
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 from Baseline and attainment of a DAS28 score of ≤ 5.1, or
an improvement (decrease) in the DAS28 of &gt; 1.2 from Baseline and attainment of a DAS28 score of &gt; 3.2.
No Response is defined as either:
an improvement (decrease) in the DAS28 of ≤ to 0.6, or
an improvement (decrease) in the DAS28 of &gt; 0.6 and ≤ 1.2 and attainment of a DAS28 of &gt; 5.1.</description>
          <population>Safety population;</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="566"/>
                <count group_id="O3" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=501)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="242"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=443)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=394)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an American College of Rheumatology (ACR) 20 Response</title>
        <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR20 could be calculated at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology (ACR) 20 Response</title>
          <description>American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 20% improvement in tender joint count;
≥ 20% improvement in swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
          <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR20 could be calculated at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=293)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an American College of Rheumatology (ACR) 50 Response</title>
        <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR50 could be calculated at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology (ACR) 50 Response</title>
          <description>American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 50% improvement in tender joint count;
≥ 50% improvement in swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
          <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR50 could be calculated at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=498)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=388)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an American College of Rheumatology (ACR) 70 Response</title>
        <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
        <time_frame>Baseline and Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR70 could be calculated at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology (ACR) 70 Response</title>
          <description>American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:
≥ 70% improvement in tender joint count;
≥ 70% improvement in swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
Acute phase reactant value (C-reactive protein [CRP]).</description>
          <population>Safety population; the analysis was performed on the basis of non-missing information and no imputation methods were used. &quot;n&quot; indicates the number of patients for whom ACR70 could be calculated at each time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=495)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=435)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=373)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Missed at Least One Dose of Humira</title>
        <description>Compliance to study treatment was measured by the percentage of participants who missed at least one dose of Humira during each time interval between study visits.</description>
        <time_frame>Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Safety population; &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Humira</title>
            <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Missed at Least One Dose of Humira</title>
          <description>Compliance to study treatment was measured by the percentage of participants who missed at least one dose of Humira during each time interval between study visits.</description>
          <population>Safety population; &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=512)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=451)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n=271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Humira</title>
          <description>Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lymph nodes enlarged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction/Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cardiac failure aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Paroxysmal upraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hypochondrium pain right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hypogastric pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Paresthesia circumoral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever/Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Weakness/Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Difficulty in walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Edema abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Edema of legs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nodule on finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Reaction unevaluable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Abscesses of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Periapical dental abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Phlegmon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Post operative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Relapsing fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Septic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Tuberculous peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Viral hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Automobile Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bimalleolar fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Elbow fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Shoulder fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Loss/Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Erythrocyte sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Transaminases increased/Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RA flare up</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pain in hip</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Arthritis single joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hydrarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Intervertebral disc herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lumbar disc herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Periarticular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Wrist deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myelomonocytic leukemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Collecting duct renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lung nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Parathyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Demyelinating disease (excl. multiple sclerosis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Movements reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Fusion lumbar spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Removal of surgical hardware</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

